Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103727 · ClinicalTrials.gov registry record · Phase 2
Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 282
- Enrollment target
NCT00103727 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 282 participants.
The verdict
NCT00103727, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 282 participants
- Enrollment target
Study Summary
This study will evaluate whether talnetant (200mg, 400mg, 600mg) twice a day is effective compared to placebo and risperidone 1-3mg twice a day in treating the positive and negative symptoms of schizophrenia. Study subjects will be treated with study drug for up to 6 weeks and will then return for a follow-up visit 2 weeks later. About 275 patients with schizophrenia will be enrolled in this study.
Interventions
- OTHER placebo
- DRUG Talnetant
- OTHER risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103727
The ClinicalTrials.gov registry entry for NCT00103727 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00103727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103727 about?
NCT00103727 is a clinical study titled "Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia". This study will evaluate whether talnetant (200mg, 400mg, 600mg) twice a day is effective compared to placebo and risperidone 1-3mg twice a day in treating the positive and negative symptoms of schizophrenia. Study subjects will be treated with study drug for up to 6 weeks and will then return for a...
What is the current status of trial NCT00103727?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 282 participants. The study started on 2004-12. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00103727?
The interventions under investigation include: placebo (OTHER), Talnetant (DRUG), risperidone (OTHER).
Who is sponsoring clinical trial NCT00103727?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.